Wexford Capital LP Buys Shares of 3,922 Apogee Therapeutics, Inc. (NASDAQ:APGE)

Wexford Capital LP acquired a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGEFree Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,922 shares of the company’s stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Apogee Therapeutics during the third quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after purchasing an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics in the second quarter worth $143,000. Arizona State Retirement System boosted its holdings in Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after purchasing an additional 258 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after buying an additional 1,340 shares in the last quarter. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Trading Up 6.0 %

NASDAQ APGE opened at $49.97 on Friday. The business’s 50-day moving average price is $52.41 and its two-hundred day moving average price is $48.31. The firm has a market capitalization of $2.25 billion, a PE ratio of -20.65 and a beta of 2.30. Apogee Therapeutics, Inc. has a 12 month low of $19.91 and a 12 month high of $72.29.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on APGE. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $110.00 target price (up from $95.00) on shares of Apogee Therapeutics in a research note on Tuesday. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Finally, Wedbush increased their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $83.88.

View Our Latest Stock Report on APGE

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $46.58, for a total transaction of $698,700.00. Following the completion of the sale, the chief executive officer now directly owns 1,324,487 shares in the company, valued at approximately $61,694,604.46. This trade represents a 1.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 6,665 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total value of $394,034.80. Following the completion of the transaction, the insider now directly owns 267,463 shares in the company, valued at $15,812,412.56. This represents a 2.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,995 shares of company stock valued at $4,912,264. 36.10% of the stock is currently owned by company insiders.

About Apogee Therapeutics

(Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

See Also

Institutional Ownership by Quarter for Apogee Therapeutics (NASDAQ:APGE)

Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.